Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 3/20 | 0.42 |
| ▸ | RARA | P10276 | 2/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.39 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | PLA2G4B | P0C869 | 2/20 | 0.36 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16644652 | 0.86 | TSHR (0.40) | TSHRTP53RECQL | |
| SCHEMBL13367288 | 0.82 | CNR2 (0.43) | RARBRARACNR2TSHRTP53 | |
| SCHEMBL15959660 | 0.81 | NOTUM (0.53) | TSHRRECQL | |
| SCHEMBL16644651 | 0.78 | MAPT (0.46) | CNR2CNOT7TP53 | |
| SCHEMBL19646277 | 0.76 | HTT (0.42) | — | |
| SCHEMBL12697313 | 0.74 | TSHR (0.51) | RARBRARACNR2TSHRTP53 | |
| SCHEMBL14846707 | 0.74 | NOTUM (0.39) | TSHRTP53 | |
| SCHEMBL17980842 | 0.71 | TSHR (0.53) | TSHRTP53RECQLPLA2G4BPTPN11 | |
| SCHEMBL15613744 | 0.70 | THRA (0.38) | CNR2TSHRTP53 | |
| SCHEMBL15613740 | 0.69 | TSHR (0.53) | TSHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9827336-B2 | Radio-pharmaceutical complexes | BAYER AS (NO) | 2017-11-28 | — | — | US | disclosed |
| US-20150147272-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2015-05-28 | — | — | US | disclosed |
| US-20150110817-A1 | RADIO-PHARMACEUTICAL COMPLEXES | BAYER AS (NO) | 2015-04-23 | — | — | US | disclosed |
| US-20150104385-A1 | RADIO-PHARMACEUTICAL COMPLEXES | ALGETA ASA (NO) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150147272-A1 | RADIO-PHARMACEUTICAL COMPLEXES | HCAR3, TYRO3, HCAR1 | RARB 1250/4885RARA 1263/4885CNR2 1684/4885 |
| US-20150104385-A1 | RADIO-PHARMACEUTICAL COMPLEXES | CD22, HAVCR2, CD2 | RARB 494/4885RARA 530/4885CNR2 830/4885 |
| US-20150110817-A1 | RADIO-PHARMACEUTICAL COMPLEXES | TSPO, TK1, HCAR1 | RARB 756/4885RARA 856/4885CNR2 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.